1,33 $
0,00 %vorgestern
Nasdaq, 1. März, 22:00 Uhr
ISIN
US09071M1062
Symbol
BLRX
Berichte
Sektor
Industrie

Bioline RX Ltd Sponsored ADR Aktie News

Neutral
PRNewsWire
4 Tage alt
- Conducted in Collaboration with Columbia University, the CheMo4METPANC Phase 2 trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies compared to chemo alone - -  Gulam Manji, MD, PhD, of Columbia University to present encore pilot phase data at the Immuno-Oncology (IO) 360° Summit on February 29 - TEL AVIV, I...
Positiv
InvestorPlace
7 Tage alt
In almost every situation, investors should stay away from penny stocks. They're extremely speculative and they tend to facilitate delusions of grandeur.
Neutral
PRNewsWire
16 Tage alt
Results include pharmacokinetic and pharmacodynamic data, and post-hoc subgroup analyses of the Phase 3 GENESIS trial   Presentations on Thursday, February 22, 2024 in San Antonio, Texas TEL AVIV, Israel , Feb. 16, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced ...
Neutral
PRNewsWire
2 Monate alt
- Proof-of-concept study is initial step toward goal of identifying more efficient CD34+ HSC mobilization regimen for patients with sickle cell disease choosing gene therapy - TEL AVIV, Israel , Dec. 21, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced tha...
Positiv
Seeking Alpha
3 Monate alt
BioLineRx gains approval for a blood cancer drug that aids in stem cell transplantation. Motixafortide, the flagship drug, shows promising results in mobilizing blood stem cells and in combination with other treatments for pancreatic cancer. Financially, BioLineRx has a limited amount of cash on hand but has secured a licensing deal that provides additional funds.
Neutral
Seeking Alpha
3 Monate alt
BioLineRx is a biopharmaceutical company specializing in cancer and rare disease therapies. The company's main product, Aphexda, was FDA-approved for stem cell mobilization in multiple myeloma patients. BioLineRx's low cash reserves and need for additional financing pose risks, but its valuation appears relatively conservative.
Neutral
Seeking Alpha
3 Monate alt
BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2023 Earnings Conference Call November 20, 2023 10:00 PM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Conference Call Participants Joe Pantginis - H.C.
Neutral
PRNewsWire
3 Monate alt
- Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma - - Closed Exclusive License Agreement for Motixafortide in Asia Region with Concurrent Strategic Equity Investment - - Presented Encouraging Data at AACR from Pilot Phase of Ran...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen